Counselors in Edmonton, KY Accepting Medicare

7 Counselors found. Showing 1 - 7

Erik Hunley, BHS Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Sartin Dr, Edmonton, KY 42129 Phone: 270-432-4951    Fax: 270-432-5054

Autumn Jordan Lynn Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Sartin Dr, Edmonton, KY 42129 Phone: 270-901-5000

Mark J Saderholm, LPCC Counselor - Professional Medicare: Medicare Enrolled Practice Location: 112 Sartin Dr., Edmonton, KY 42129 Phone: 270-432-4951    Fax: 270-432-5054

Rita Milby, LPCA Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Sartin Dr., Edmonton, KY 42129 Phone: 270-432-4951    Fax: 270-432-5054

Chastity Renee Munoz, LPCC Counselor Medicare: Not Enrolled in Medicare Practice Location: 112 Sartin Dr, Edmonton, KY 42129 Phone: 270-901-5000    Fax: 270-842-5268

Genevieve Thomas, LPCA Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 112 Sartin Dr, Edmonton, KY 42129 Phone: 270-432-4951    Fax: 270-432-5054

James Michael Pasley, LPP Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: Metcalfe County Service Center, 112 Sartin Dr, Edmonton, KY 42129 Phone: 270-432-4951    Fax: 270-432-5054

News Archive

Study finds malaria drug does not affect the ability of airline crew to perform their duties

Results from a new study presented today at the 75th Annual Scientific Meeting of the Aerospace Medical Association (AsMA) in Anchorage, USA, suggest that MalaroneTM (atovaquone and proguanil hydrochloride) would not be expected to affect the ability of pilots and cabin crew to perform their duties while on an aircraft.

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

COVID-19 vaccine hesitancy in UK varies significantly between population subgroups

Researchers investigating attitudes towards vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the UK population have found that, overall, most people were willing to accept a vaccine.

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

Read more Medical News

› Verified 6 days ago